Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) — a rare, devastating form of dementia that strips patients of their ability to speak — showed stable plasma NfL levels over 24 weeks. Notably, patients with the highest drug exposure actually saw a decline in this key neurodegeneration marker. There are currently no approved disease-modifying therapies for nfvPPA.
A rare and cruel form of dementia called nonfluent variant primary progressive aphasia (nfvPPA) leaves patients fully aware as they progressively lose the ability to speak — and right now, there's nothing to slow it down. That may be starting to change. Interim 24-week data from an ongoing phase 2a trial presented at the CTAD 2026 conference showed that neflamapimod, an investigational oral drug that targets neuroinflammation, kept plasma neurofilament light chain (NfL) — a key marker of brain cell damage — stable in nfvPPA patients.
The most striking finding: patients with the highest drug exposure (the top third by blood concentration) saw a median NfL decrease of 4.5 pg/mL, while those with lower exposure had a median increase of 4.35 pg/mL. For context, untreated nfvPPA typically causes NfL to rise ~9 pg/mL per year. The drug was generally well tolerated, with no serious adverse events.
By the Numbers:
Why it matters: With no approved treatments for nfvPPA, even early biomarker signals are meaningful. The exposure-response pattern suggests the drug may be hitting its biological target — and higher doses being planned for future studies could amplify that effect. Full clinical results are expected at the AD/PD conference in March 2027.